KAKadri Altundag

Kadri Altundag

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Kadri Altundag has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

    • 9 June 2016
      • Vol. 21  (2) , 375-81

    Efficacy and safety of eribulin monotherapy in patients with heavily pretreated metastatic breast cancer.

    by Ozturk Ates, Taner Babacan, Neyran Kertmen, Furkan Sarici, Alma Cenoli, Serkan Akin, Yusuf Karakas, Saadettin Kilickap, Yavuz Ozisik, Ali R Sever, et al.

    Eribulin is a non-taxane microtubule inhibitor, which can be used after anthracycline and taxane treatment in patients with metastatic breast cancer (MBC). The purpose of this study was to investigate the efficacy and safety of eribulin monotherapy in heavily pretreated MBC patients. In this single-center trial, a total of 66 MBC patients who received eribulin monotherapy in Hacettepe University Cancer Institute between 2013 and 2015 were retrospectively analyzed. Kaplan-Meier survival analysis was carried out for progression free survival (PFS) and for overall survival (OS). Two-sided p values <0.05 were considered as statistically significant. Sixty-six patients who received at least one cycle of eribulin were registered. Most patients were heavily pretreated with a median of 4 (range 2-7) previous chemotherapy lines prior to eribulin. Median patient age was 50 years (range 28-67). Most patients were treated with eribulin at 4th or 5th line (33.3 and 27.3%, respectively). Brain metastases were present in 19 (28.8%) patients at the time of initial eribulin administration. Median PFS was 5 (95% CI 4.1-5.8) and median OS was 8 (95% CI 6-9.9) months. Fifteen patients (22.7%) responded to treatment with partial remission (PR) and 36 (54%) had stable disease (SD). No hypersensitivity reactions and no toxic deaths were observed. Three (5%) patients experienced grade 4 neurotoxicity. Fourteen (21.5%) patients developed grade 3-4 neutropenia. Eribulin monotherapy is an effective and safe regimen for MBC patients. Its low toxicity profile compared to other intravenous cytotoxic agents and the ease in its intravenous administration make this agent a preferable option for both physicians and patients.


    • 9 June 2016
      • Vol. 21  (2) , 520

    Leg cramps associated with tamoxifen use--possible mechanism and treatment recommendations.

    by Fatih Karatas, Suleyman Sahin, Taner Babacan, Serkan Akin, Ali R Sever, Kadri Altundag


    • 9 June 2016
      • Vol. 21  (2) , 521

    When should we give aromatase inhibitors for insomnia; early in the day or after dinner?

    by Ozturk Ates, Veli Sunar, Ali R Sever, Kadri Altundag

  • Obesity as an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.

    by Fatih Karatas, Gokmen Umut Erdem, Suleyman Sahin, Aydin Aytekin, Deniz Yuce, Ali Riza Sever, Kadri Altundag

    1029 Background: The relation between body mass index (BMI) and pathological complete response (pCR) to neoadjuvant chemotherapy (NAC) in breast cancer (BC) is a controversial issue. The aim of this study is to evaluate BMI and pCR to NAC and discuss the importance of pCR outcomes in Turkish BC patients. Methods: Of the 4423 BC patients diagnosed between the years 1994 and 2015 in Oncology Center of University of Hacettepe, 295 female patients with stage II and III BC were enrolled in the study. Three different group divisions were done according to patients BMI, as normal and underweight (N/U; < 25 kg/m2), overweight (OW; 25 - 29.9 kg/m2) and obese (OB; ≥ 30 kg/m2). The analysis of overall survival (OS) and recurrence-free survival (RFS) were performed according to Kaplan-Meier method. The Log-rank test was used to compare the subgroup analysis and logistic regression analysis to determine independent prognostic factor analysis. Results: In this study, a total number of 93 (31.5%) patients were N/U, 107 (36.3%) patients were OW and 95 (32.2%) patients were OB. In the multivariate logistic regression analysis, OB was an independent worse prognostic feature on pCR to NAC compared to N/U patients. (OR: 0.34, 95%CI: 0.13 to 0.85; P = 0.02). Median RFS and median OS was significantly higher in N/U patients compared to OB patients (RFS: 150 vs. 76 months respectively; P = 0.03 and OS; N/U = not reached vs. OB = 114 months; P = 0.01) and were also higher in pCR group compared to non-pCR patients (RFS: 151 vs. 77 months; P = 0.004 and OS: not reached vs. 211 months; P = 0.04). In cox regression analysis; pCR, histopathologic grade and TNBC were found independent prognostic factor on OS (HR: 0.29, 95%CI: 0.11 to 0.79, P = 0.015, HR: 2.09, 95%CI: 1.14 to 3.83, P = 0.017, HR: 1.95, 95%CI: 1.01 to 3.77, P = 0.046, respectively). Conclusions: It was observed that obesity was a strongly important independent prognostic factor for lower likelihood of pCR. Obesity causes a decrease both in RFS and OS in patients with BC who receive NAC. The probability of chemotherapy resistance and inefficient treatment in obese patients should be considered.

  • Clinicopathological features of patients with breast cancer aged 70 years and older: A single center experience.

    by Aydin Aytekin, Suleyman Sahin, Fatih Karatas, Gokmen Umut Erdem, Ali Riza Sever, Kadri Altundag

    E12060 Background: It is well-known that the risk of breast cancer (BC) increases in parallel with aging. In addition, life expectancy is increasing worldwide.Despite this disease burden in elderly patients, there is still a great uncertainty regarding how to manage BC disease in the older population.We aimed to report clinicopathological features and treatment outcomes of our experience in BC patients aged over 70 years. Methods: Medical records of 4413 patients with BC followed between 1994 – 2015 were retrospectively analyzed. Of these, 238 patients (stage 1-3) aged 70 years and older at BC diagnosis were enrolled in the study. Patients were divided into 2 groups according to age as group 1 (between 70 – 79, n = 192) and group 2 (80 and older, n = 46). Clinicopathological features of patients including tumor histology,grade, estrogen and progesteron receptor, HER2 status, tumor size, lymph node involment, clinical stage, type of treatments and comorbid diseases along with familial history were evaluated. Results: The median age was 74 for group 1 (70 - 79) and 82 for group 2 (80 - 92). Number of patients with a familial breast cancer history was significantly greater in group 1 in comparison to group 2 (P = 0.028). Patients in group 2 more frequently presented with greater tumor size (P = 0.014). Modified radical mastectomy and adjuvant chemotherapy treatments were more commonly performed in group 1 (P = 0.001, P = 0.001, respectively). In contrast, neoadjuvant treatment was more frequently applied in group 2 (P = 0.003). While there was no difference in disease free survival between the groups, median overall survival was significantly higher in group 1 (P = 0.03). In addition, there was no difference in other clinicopathologic features between two groups. Conclusions: Given the increasing life time of older population in BC patients, it is apparently necessary to establish the most appropriate algorithms for treatment options in this group of patients. In order to set up a better treatment algorithm for this population, more comprehensive studies including large number of older patients with a complete geriatric assessments should be performed.


  • The impact of the total size of lesions in multifocal/multicentric breast cancer on survival.

    by Yusuf Karakas, Omer Dizdar, Serkan Akin, Ozturk Ates, Mehmet Ali Nahit Sendur, Sercan Aksoy, Mutlu Hayran, Ibrahim Halil Gullu, Yavuz Yasin Ozisik, Kadri Altundag

    E12030 Background: Multifocal/multicentric(MF/MC) may be observed in 20% of patients with breast cancer.According to AJCCstaging system, the T stage of a tumor is determined based on the size of the largest lesion in the breast; however, some data suggest that considering the total size of the lesions is more valuable.We investigated and compared the prognostic value of determining the T stage according to the total size of lesions and according to the size of the largest lesion alone in patients with MF/MC breast cancer. Methods: The pathology reports of patients with breast cancer who were monitored at Hacettepe University 2003 and 2014 were reviewed. The T stage of MF/MC tumors was determined according to the largest lesion size (Tfirst ) and the sum of the longest diameters of the lesions (Tlast ). The impact of both T stages on DFS and OS was evaluated. Results: MF/MC tumors were diagnosed in 323 of 3890 patients with breast cancer (8.3%). When the T stage was determined by summing the sizes of the lesions, the T stage of 67 (20.7%) and 63 (19.5%) patients advanced from T1 to T2 and T2 to T3, respectively. Thus, the T stage in a total of 130 patients with MF/MC (40.2%) increased (32 patients from AJCC stage I to II and 13 patients from stage II to III). AJCC stage changed in a total of 45 patients (14%). In patients with unifocal and MF/MC tumors, the 10-year OS was 75% and 74%, respectively (p = 0.965) and the 10-year DFS was 66% and 61%,respectively (p = 0.817). It was observed that the DFS curves of the patients with MF/MC tumors whose T stage advanced from phase I to II according to Tfirst and Tlast (n = 32) overlapped with the survival curves of the patients with unifocal tumors whose was stage I, particularly in the first 3 years. The 3-year DFS was found to be 97.2% in patients with unifocal tumors of stage 1, 91.6% in patients with stage 2, and 100% in patients whose multifocal stage advanced from I to II according to Tlast . The independent predictors of DFS were found to be Tfirst , hormone receptor positivity, and lymph node involvement. There was no significant relationship between Tlast and DFS. Conclusions: It was observed that the T stage obtained by summing lesion sizes in patients with MF/MC breast cancer is not superior to the classic staging in terms of prognosis.


  • Comparison of clinical outcomes in patents with early stage ER-/PR+, HER2- breast cancer patients with triple negatives.

    by Ozan Yazici, Gokmen Umut Erdem, Sercan Aksoy, Mehmet Ali Nahit Sendur, Nuriye Özdemir, Mutlu Dogan, Nurullah Zengin, Kadri Altundag

    E12556 Background: Although ER-/PR+, HER2- breast cancer patients are treated as hormone receptor positive patients, clinically they behave more aggressive than classic hormone receptor+ tumors.We aimed to retrospectively compare the clinical features and survival rates of the early stage ER-/PR+/HER2 - breast cancer patients with triple negatives. Methods: In between 2002 - 2015, the clinical data of triple negative early breast cancer patients retrospectively compared to ER-/PR+, HER2-. Patients having ER+ or HER2+, metastatic stage at time of diagnosis were excluded. Results: Total 518 patients were included in study [triple negative (n = 348) , ER-/PR+, HER2:- (n = 170)]. Median follow up time was 51 (min:4.4-max: 346.3) months.Mean age, the rate of patients with most common histological subtype (ductal), pre and postmenopausal status, TNM Tumor stage [(Triple(-) vs ER-/PR+, HER2:-, T1 (28.9% vs 25.1%), T2 (54% vs 52.1%), T3 (15.3% vs 17.4%), T4 (1.8% vs 5.4%)] and rate of patients having adjuvant radiotherapy (70.3% vs 71.2) and chemotherapy (93.4% vs 92.4%) was similar in between triple(-) and ER-/PR+,HER2:- patient group.The ratio of patients having grade 3 (75% vs 56.9%) disease, lmyphovascular invasion, negative pathological lymph node (50.6% vs 36.5%) was higher in triple (-) compared to ER-/PR+, HER2:- (p < 0.001).Overall survival(OS) rate at 1.st, 3.th, 5.th and 10.th year in triple(-) and ER-/PR+, HER2:- group were %97 vs %100, %88 vs %87, %82 vs %80, %69 vs %61, respectively (p = 0.17). However, following the 6.th year survival difference was prominently increased in favor of triple(-). Median disease free survival (DFS) rate in triple(-) and ER-/PR+, HER2:- was 166 (95% CI, 132.3-200.5), 115 (95% CI, 66.6-165.2) months (p = 0.49). Following 6. th year DFS rate was markedly increased in favor of triple group (10th year DFS rate; triple(-) vs ER-/PR+/HER2:- 62% vs 47%). Conclusions: In our preliminary results we hypothesized that early stage triple(-) breast cancer patients have similar clinical outcomes with ER-/PR+, HER2- patients. The reasons of the increased DFS and OS rate in favor of triple(-) group following the 6th year of diagnosis might be evaluated in future randomized trials.

    • 12 April 2016
      • Vol. 21  (1) , 17-20

    Current management of aromatase inhibitor-induced arthralgia.

    by Suleyman Sahin, Fatih Karatas, Ali R Sever, Kadri Altundag

    Aromatase inhibitors (AIs) are standard of care in the adjuvant setting of postmenopausal women with hormone receptor positive breast cancer. Despite their beneficial effects on survival outcomes in breast cancer, AIs-induced arthralgia (AIA) is a common side effect which may lead to drug discontinuation and decreased AIs adherence among patients. So far, the exact pathophysiology of AIA is still an unclarified condition that explains why the optimal treatment in its management has not yet been established. Moreover, studies regarding the alternative treatment options for AIA are limited due to small sample size. Herein, we report a summary of current treatment options and their effectiveness in AIA with a practical algorithm in light of the relevant literature.


    • 9 February 2016
      • Vol. 20  (6) , 1640

    Insomnia caused by aromatase inhibitors; a therapeutic challenge in patients with breast cancer.

    by Fatih Karatas, Suleyman Sahin, Taner Babacan, Serkan Akin, Ali R Sever, Kadri Altundag